- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00849147
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Leukemia and lymphoma are types of blood cancers. Chemotherapy is a common treatment option for people with these types of cancers, but if the cancer does not respond well to chemotherapy, or if the cancer returns, a bone marrow transplant is another treatment option. In a bone marrow transplant procedure, healthy bone marrow is taken from a donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who has a similar type of bone marrow. Most bone marrow transplants are performed using a donor who is a perfect or close-to-perfect tissue match. However, for participants in this study, researchers have determined that a completely matched donor is unavailable within participants' families, and an unrelated donor match has not been found either. Participants do, however, have a family member who is a partial tissue match. Typically, people who are undergoing a bone marrow transplant receive high doses of chemotherapy before the transplant to prepare their bodies to accept the donor bone marrow. In this study, participants will undergo a new type of bone marrow transplant called a nonmyeloablative transplant, which is a reduced intensity method of transplantation that does not require high doses of chemotherapy. The purpose of the study is to examine the safety and effectiveness of a nonmyeloablative bone marrow transplant that uses partially matched bone marrow donated by a family member as a treatment option for people with leukemia or lymphoma.
This study will enroll people with leukemia or lymphoma who have a family member with a partial tissue match. Participants will be admitted to the hospital and will first receive a type of chemotherapy called fludarabine, which will be given intravenously for 5 days. In addition, another type of chemotherapy, cyclophosphamide, will be given intravenously on the first and second day. After 5 days, participants will receive a small dose of radiation. The next day, participants will undergo the bone marrow transplant. The third and fourth day after the transplant, participants will receive high doses of cyclophosphamide to help prevent two complications, graft rejection, which occurs when the body's immune system rejects the donor bone marrow, and graft-versus-host disease (GVHD), which is an attack by the donor cells on the body's normal tissues. On the fifth day after the transplant, participants will receive two additional medications, tacrolimus and mycophenolate mofetil (MMF), to help prevent GVHD; some participants may receive cyclosporine instead of tacrolimus. Participants will receive MMF for about 5 weeks and tacrolimus for about 6 months. Also beginning on the fifth day after the transplant, participants will receive daily injections of a growth factor called granulocyte-colony stimulating factor (G-CSF), which is a natural protein that increases the white blood cell count; G-CSF will be continued until a participant's white blood cell count is normal again.
Participants will remain in the hospital for approximately 2 to 3 months, but possibly longer if there are complications. While participants are in the hospital, blood samples will be collected regularly to evaluate the response and possible side effects to treatment, including GVHD. If necessary, participants will receive platelet and red blood cell transfusions. Follow-up study visits will occur 6 months and 1 year after the transplant. At Months 1, 2, 6, and 12 after the transplant, blood or bone marrow samples will be obtained. Study researchers will keep track of participants' medical condition through phone calls or mailings to participants and their doctors once a year for the rest of the participants' lives.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope National Medical Center
-
La Jolla, California, United States, 92093
- University of California San Diego Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32610-0277
- University of Florida College of Medicine (Shands)
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Bone Marrow Transplant Group of Georgia, Northside Hospital
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96826
- Kapi'olani Medical Center for Women and Children, University of Hawaii
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Greenbaum Cancer Center
-
Baltimore, Maryland, United States, 21231
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center (SKCCC)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- DFCI, Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute, Children's Hospital of Michigan
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University, Barnes Jewish Hospital
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111-2442
- Fox Chase, Temple University
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-8210
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center
-
San Antonio, Texas, United States, 78229
- Texas Transplant Institute
-
-
Washington
-
Seattle, Washington, United States, 98109-1024
- Fred Hutchinson Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be 21 to 70 years old; participants 1 to 21 years old are also eligible if they are ineligible for BMT CTN #0501 (NCT00412360)
- Donor must be at least 18 years of age
- Human leucocyte antigen (HLA) typing will be performed at high resolution (allele level) for the HLA-A, -B, Cw, DRB1, and -DQB1 loci. A minimum match of 5/10 is required. An unrelated donor search is not required for a person to be eligible for this study if the clinical situation dictates an urgent transplant. Clinical urgency is defined as 6 to 8 weeks from referral to transplant center or low likelihood of finding a matched, unrelated donor. The donor and recipient must be identical, as determined by high resolution typing, on at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. Fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype, and typing of additional family members is not required.
- Must have received cytotoxic chemotherapy within 3 months of the consent date (measured from the start date of chemotherapy)
- Acute leukemias (includes T lymphoblastic lymphoma) in the second or subsequent complete remission (CR)
- Burkitt's lymphoma in the second or subsequent CR
- Lymphoma
Patients with adequate physical function as measured by the following:
- Heart: left ventricular ejection fraction at rest must be greater than or equal to 35%, or shortening fraction greater than 25%
- Liver: bilirubin less than or equal to 2.5 mg/dL and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase less than five times the upper limit of normal
- Kidney: serum creatinine within normal range for age, or if serum creatinine is outside the normal range for age, then kidney function (creatinine clearance or glomerular filtration rate (GFR) is greater than 40 mL/min/1.73m^2
- Pulmonary: forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and carbon monoxide diffusing capacity (DLCO) greater than 50% predicted (corrected for hemoglobin). If unable to perform pulmonary function tests, then oxygen (O2) saturation must be greater than 92% on room air.
- Performance status: Karnofsky/Lansky score greater than or equal to 60%
Exclusion Criteria:
- Have an HLA-matched, related, or 7 or 8/8 allele matched (HLA-A, -B, -Cw, -DRB1) related donor able to donate
- Had an autologous hematopoietic stem cell transplant in the 3 months before study entry
- Pregnant or breastfeeding
- Evidence of HIV infection or known HIV positive serology
- Current uncontrolled bacterial, viral, or fungal infection (i.e., currently taking medication with evidence of progression of clinical symptoms or radiologic findings)
- Prior allogeneic hematopoietic stem cell transplant
- History of primary idiopathic myelofibrosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Haploidentical Bone Marrow Transplant
Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
|
The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.
Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor. The GVHD prophylaxis regimen will consist of the following:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival at 180 Days From the Time of Transplant
Time Frame: Measured at Month 6 and Year 1
|
Measured at Month 6 and Year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Donor Cell Engraftment
Time Frame: Measured at Day 56
|
Marrow or Blood Sample.
Donor cell engraftment is defined as donor chimerism ≥ 5% on Day ≥ 56 after transplantation.
Chimerism should be evaluated on Days ~28, ~56, ~180, and ~365 after transplantation.
Chimerism may be evaluated in whole blood or mononuclear fraction.
|
Measured at Day 56
|
Acute Graft-versus-host Disease (GVHD)
Time Frame: Measured at Day 100
|
Measured at Day 100
|
|
Chronic GVHD
Time Frame: Measured at Year 1
|
Measured at Year 1
|
|
Treatment-related Mortality (TRM)
Time Frame: Measured at 6 months and 1 year
|
Measured at 6 months and 1 year
|
|
Neutrophil Recovery
Time Frame: Measured at Days 28, 56, 90, and 100
|
Cumulative incidence of neutrophil recovery >500/μL at day +56
|
Measured at Days 28, 56, 90, and 100
|
Primary Graft Failure
Time Frame: Measured at Day 67
|
Primary graft failure is defined as < 5% donor chimerism on all measurements.
|
Measured at Day 67
|
Secondary Graft Failure
Time Frame: Measured at Day 100
|
Secondary graft failure is defined as initial recovery followed by neutropenia with < 5% donor chimerism.
If no chimerism assays were performed and absolute neutrophil count is < 500/mm3, then it will be counted as a secondary graft failure.
|
Measured at Day 100
|
Platelet Recovery
Time Frame: Measured at Days 56, 90, and 100
|
Platelet Recovery to 20K
|
Measured at Days 56, 90, and 100
|
Platelet Recovery
Time Frame: Measured at Days 56, 90, and 100
|
Platelet Recovery to 50K
|
Measured at Days 56, 90, and 100
|
Progression-free Survival
Time Frame: Measured at Year 1
|
Progression-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.
|
Measured at Year 1
|
Infections
Time Frame: Measured at Year 1
|
Number of infections; infections will be reported by anatomic site, date of onset, organism and resolution, if any.
Patients will be followed for infection for 1 year post-transplant.
|
Measured at Year 1
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.
- Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, Fuchs EJ. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014 Oct;20(10):1485-92. doi: 10.1016/j.bbmt.2014.05.015. Epub 2014 May 23.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- DNA Virus Infections
- Tumor Virus Infections
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Burkitt Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Other Study ID Numbers
- BMTCTN0603
- U01HL069294 (U.S. NIH Grant/Contract)
- 5U24CA076518 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Informed Consent Form (ICF)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Follicular
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Epizyme, Inc.RecruitingFollicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular LymphomaUnited States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
Clinical Trials on Haploidentical Bone Marrow Transplantation
-
Massachusetts General HospitalRecruitingBone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)Autoimmune Diseases | Multiple Myeloma | Hodgkin Disease | AL Amyloidosis | Myelofibrosis | Chronic Kidney Disease | Sickle Cell Anemia | Thalassemia | Aplastic Anemia | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Non-Hodgkin... and other conditionsUnited States
-
Odense University HospitalCompletedMyocardial Ischemia | Heart Failure, CongestiveDenmark
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAvailableMalignant Neoplasm | Hematopoietic Cell Transplantation Recipient | Benign Neoplasm | Bone Marrow Transplantation RecipientUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host DiseaseUnited States
-
University of MiamiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Diabetes...TerminatedType 1 Diabetes MellitusUnited States
-
Fundacion para la Formacion e Investigacion Sanitarias...Carlos III Health Institute; Hospital Universitario Virgen de la Arrixaca; Hospital... and other collaboratorsCompletedAmyotrophic Lateral SclerosisSpain
-
Institute of Hematology & Blood Diseases HospitalRecruiting
-
Vinmec Research Institute of Stem Cell and Gene...Vinmec Health Care System (Vingroup Joint Stock Company)Completed
-
Neurogen Brain and Spine InstituteWithdrawnCerebrovascular AccidentIndia
-
Translational Research Center for Medical Innovation...Terminated